Companies: 10,795·Total market cap: $144.5T
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMRNASDAQHealthcare● Active
$73.95
$-0.18(-0.24%)
Market Cap$6.1B
P/E Ratio
52W High$103
52W Low$36.65
Overview

Kymera Therapeutics, Inc. (KYMR) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KYMR · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-3.58kymr eps ttm · kymr earnings per shareEarnings history
PE Ratio (TTM)kymr pe ratio ttm · kymr price to earningsPE Ratio deep dive
Revenue (TTM)$51.5Mkymr revenue ttm · kymr annual revenueFull revenue history
Dividend YieldNo Dividenddoes kymr pay dividends · kymr dividend yieldDividend history
Shares Outstanding84.4Mkymr shares outstanding · kymr floatShares outstanding history
Next EarningsAug 10, 2026Est.kymr earnings date · kymr next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$39.2M▼ 16.72% YoY
202320242025
kymera therapeutics, inc. revenue · kymr revenue 2025
FY 2025Net Income-$311.4M▼ 39.11% YoY
202320242025
kymera therapeutics, inc. net income · kymr profit 2025
FY 2025EPS$-3.69▼ 23.83% YoY
202320242025
kymr eps · kymera therapeutics, inc. earnings per share 2025
TTM:Revenue: $51.5MNet Income: -$315.1MEPS: $-3.58View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy26 analystsis kymr a buy · kymr analyst rating
Strong Buy
0
Buy
23
Hold
3
Sell
0
Strong Sell
0
12-Month Price Target
$97.00Low
$73.95Current
$117.38Avg Target58.73% upside
$134.00High
kymr price target · kymr 12 month forecast

Total: 26 · Buy rate: 88.5%

The KYMR analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month price target is $117.38, representing +58.73% upside from the current price of $73.95.

Stock Performance

Full History
1D-0.24%
1W+4.18%
1M-14.09%
3M-11.43%
YTD-4.96%
1Y+56.81%
5Y+52.32%

About Kymera Therapeutics, Inc.

CEONello Mainolfi
IPO DateAug 21, 2020
Employees208
CountryUS

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent prot…

what is kymera therapeutics, inc. · kymr stock overview · kymera therapeutics, inc. company profile · who is kymera therapeutics, inc. ceo · kymr NASDAQ · kymera therapeutics, inc. headquarters · kymera therapeutics, inc. business segments

About Stock Overview & Key Data

Kymera Therapeutics, Inc. (KYMR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 21, 2020. As of the latest trading session, KYMR stock price is $73.95, with a market capitalization of $6.1B. The stock has returned +56.81% over the past 12 months and -4.96% year-to-date.

According to 26 Wall Street analysts, the consensus rating for Kymera Therapeutics, Inc. stock is Buy, with an average 12-month price target of $117.38. In fiscal year 2025, Kymera Therapeutics, Inc. reported revenue of $39.2M and net income of -$311.4M. For detailed data — including Kymera Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Kymera Therapeutics, Inc. (KYMR) stock price is $73.95. The stock is traded on NASDAQ under the ticker symbol KYMR. The 52-week range is $36.65 – $103.00.

KYMR stock priceKYMR quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice